Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 5
1995 4
1996 7
1997 3
1998 6
1999 4
2000 12
2001 9
2002 14
2003 16
2004 23
2005 24
2006 19
2007 22
2008 22
2009 23
2010 20
2011 17
2012 8
2013 13
2014 10
2015 9
2016 12
2017 5
2018 12
2019 4
2020 2
2021 10
2022 11
2023 5
2024 10
2025 13
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

337 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Rubino D, et al. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. JAMA. 2021. PMID: 33755728 Free PMC article. Clinical Trial.
Treatment of obesity and metabolic-associated fatty liver disease with a diet or orlistat: A randomized controlled trial.
Feng X, Lin Y, Zhuo S, Dong Z, Shao C, Ye J, Zhong B. Feng X, et al. Am J Clin Nutr. 2023 Apr;117(4):691-700. doi: 10.1016/j.ajcnut.2023.02.008. Epub 2023 Feb 11. Am J Clin Nutr. 2023. PMID: 36781126 Free article. Clinical Trial.
OBJECTIVES: This study aimed to compare the effects of orlistat or an experimental high-protein/lower-carbohydrate diet with a control diet in Asian patients with obesity and MAFLD. ...The absolute decrease in LFC in the orlistat group was 9.1% and 5.4% in the exper …
OBJECTIVES: This study aimed to compare the effects of orlistat or an experimental high-protein/lower-carbohydrate diet with a contro …
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Sjöström L, et al. Lancet. 1998 Jul 18;352(9123):167-72. doi: 10.1016/s0140-6736(97)11509-4. Lancet. 1998. PMID: 9683204 Clinical Trial.
Total cholesterol, low-density lipoprotein (LDL) cholesterol, LDL/high-density lipoprotein ratio, and concentrations of glucose and insulin decreased more in the orlistat group than in the placebo group. Gastrointestinal adverse events were more common in the orlistat …
Total cholesterol, low-density lipoprotein (LDL) cholesterol, LDL/high-density lipoprotein ratio, and concentrations of glucose and insulin …
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Torgerson JS, et al. Diabetes Care. 2004 Jan;27(1):155-61. doi: 10.2337/diacare.27.1.155. Diabetes Care. 2004. PMID: 14693982 Clinical Trial.

Analyses were by intention to treat. RESULTS: Of orlistat-treated patients, 52% completed treatment compared with 34% of placebo recipients (P < 0.0001). ...Mean weight loss after 4 years was significantly greater with orlistat (5.8 vs. 3.0 kg with placebo; P &lt

…
Analyses were by intention to treat. RESULTS: Of orlistat-treated patients, 52% completed treatment compared with 34% of placebo reci …
Effect of Orlistat on anthropometrics and metabolic indices in children and adolescents: a systematic review and meta-analysis.
Nikniaz Z, Nikniaz L, Farhangi MA, Mehralizadeh H, Salekzamani S. Nikniaz Z, et al. BMC Endocr Disord. 2023 Jul 7;23(1):142. doi: 10.1186/s12902-023-01390-7. BMC Endocr Disord. 2023. PMID: 37420181 Free PMC article.
Experimental and semi-experimental studies were included if they evaluated the effect of Orlistat on obesity-related parameters in children and reported the before and after anthropometric values. ...However, there were no significant effects of orlistat on body wei …
Experimental and semi-experimental studies were included if they evaluated the effect of Orlistat on obesity-related parameters in ch …
Orlistat and sibutramine beyond weight loss.
Mannucci E, Dicembrini I, Rotella F, Rotella CM. Mannucci E, et al. Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):342-8. doi: 10.1016/j.numecd.2007.03.010. Epub 2007 Oct 24. Nutr Metab Cardiovasc Dis. 2008. PMID: 17928208
In addition, orlistat determines a significant reduction of total cholesterol, independent of weight loss itself. These observations indicate that orlistat is a useful adjunctive tool for improving cardiovascular risk factor profiles in overweight and obese patients …
In addition, orlistat determines a significant reduction of total cholesterol, independent of weight loss itself. These observations …
Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials.
Noori S, Mirzababaei A, Amini MR, Clark CCT, Mirzaei K. Noori S, et al. Int J Clin Pract. 2021 Nov;75(11):e14674. doi: 10.1111/ijcp.14674. Epub 2021 Aug 24. Int J Clin Pract. 2021. PMID: 34324762
Obesity increases the risk of hyperuricemia while weight loss (>5 kg) has been reported to decrease urate. The effects of orlistat on serum uric acid (SUA) are still controversial. The aim of this meta-analysis was to evaluate the influence of orlistat on SUA lev …
Obesity increases the risk of hyperuricemia while weight loss (>5 kg) has been reported to decrease urate. The effects of orlistat …
Efficacy and safety of orlistat in controlling the progression of prediabetes to diabetes: A meta-analysis and systematic review.
Gao Z, Huang M, Wang J, Jia H, Lv P, Zeng J, Ti G. Gao Z, et al. Medicine (Baltimore). 2024 May 24;103(21):e38354. doi: 10.1097/MD.0000000000038354. Medicine (Baltimore). 2024. PMID: 38787971 Free PMC article.
BACKGROUND: The aim of this study is to examine the impact of the Orlistat on glucose levels and glucose tolerance in individuals with prediabetes, as well as assess its efficacy and safety in preventing the progression to diabetes. ...CONCLUSIONS: In prediabetic people, t …
BACKGROUND: The aim of this study is to examine the impact of the Orlistat on glucose levels and glucose tolerance in individuals wit …
Effects of orlistat on blood pressure: a systematic review and meta-analysis of 27 randomized controlled clinical trials.
Sahebkar A, Simental-Mendía LE, Kovanen PT, Pedone C, Simental-Mendía M, Cicero AFG. Sahebkar A, et al. J Am Soc Hypertens. 2018 Feb;12(2):80-96. doi: 10.1016/j.jash.2017.12.002. Epub 2017 Dec 14. J Am Soc Hypertens. 2018. PMID: 29275922
The aim of the present meta-analysis was to evaluate and quantify the BP decrease associated with orlistat use in randomized controlled trials. The search included PubMed-Medline, Scopus, Web of Science and Google Scholar databases by up to June 05, 2017, to identify rando …
The aim of the present meta-analysis was to evaluate and quantify the BP decrease associated with orlistat use in randomized controll …
337 results